Skip to main content
IPOS logo
IPOS
(NYSEARCA)
Renaissance International IPO ETF
$22.90-- (--)
Loading... - Market loading

IPOS ETF: Renaissance International IPO ETF - Price, Holdings & Analysis

Renaissance International IPO ETF Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$23.27 - $23.39
52-Week High$26.25
52-Week Low$15.14
Open$23.30
Volume1.93K
Average Volume (3M)4.93K
Assets (AUM)11.61M
Expense Ratio0.80%
Total Holdings50
Inception DateOct 5, 2014
1 Day Change-2.71%
1 Month Change-9.62%
6 Month Change25.44%
YTD Change34.66%
1 Year Change52.71%
52-Week Change52.37%
5 Year Change-34.27%
10 Year Change26.72%
50-Day MA$23.39
200-Day MA$19.61
RSI40.58
Stochastic %K8.28
Stochastic %D9.15
Annual Dividend$0.09
Dividend Yield0.40%
Last Dividend Ex-DateJun 12, 2026
Dividend Growth YoY-46.59%
Years Dividend Growth2

Frequently Asked Questions About Renaissance International IPO ETF

What is the current price of IPOS?

The latest IPOS price is $23.39. The 52-week range is $15.13–$26.25. IPOS has returned 52.4% over the past 52 weeks.

What is the expense ratio for IPOS?

IPOS's annual expense ratio is 0.80%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.

Does IPOS pay dividends?

Yes, IPOS pays a 0.40% dividend yield. The last ex-dividend date was 2026-06-12. View full dividend history in the Dividends section.

What are the top holdings of IPOS?

IPOS's largest holdings are Kioxia Holdings Corporation (24.3%), Kioxia Holdings Corporation (15.9%), Galderma Group AG Registered Shares (9.1%) (combined weight: 49.3%). The fund holds 50 total positions. View the complete portfolio breakdown in the Holdings section.

How does IPOS compare to similar ETFs?

Compare IPOS (0.80% expense ratio, $12M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.